Drugs / 111In-ibritumomab tiuxetan
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01490723 | Jan 2013 → Apr 2019 | leukemia, lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 111In-ibritumomab tiuxetan | “111In-ibritumomab tiuxetan is like 90Y- ibritumomab tiuxetan, but the radioactive particle that is attached to it does not kill lymphoma cells.” NCT01490723 ↗ |
| Route | Intravenous | “You will then receive 111In-ibritumomab tiuxetan by vein over 30 minutes.” NCT01490723 ↗ |